Birmingham, AL, United States of America

Ilya V Frolov

This inventor holds 21 USPTO granted patents and 3 published patent applications, plus 3 CIPO patents and 5 EPO patents, primarily in Alphavirus Research. Top assignees: The University of Texas System, Novartis Vaccines & Diagnostics, Gmbh, The UAB Research Foundation (The University of Alabama at Birmingham). Active years: 2002-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ilya V Frolov. Retrieved from https://idiyas.com/inventor/ilya-v-frolov

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 21 (Patent Applications = 3)

% Patents Active = 76.2

CIPO Patents = 3 (Patent Applications = 2)

EPO Patents = 5 (Patent Applications = 6)

Average Co-Inventor Count = 3.0

ph-index = 11

Forward Citations = 277(Granted Patents)

Location History:

St. Louis, MO (US) (2002 - 2014)
Galveston, TX (US) (2005 - 2016)
Birmingham, AL (US) (2013 - 2020)

Company Filing History:

9 out of 5,640

The University of Texas System

patents

2 out of 245

Novartis Vaccines & Diagnostics, Gmbh

patents

2 out of 641

The UAB Research Foundation (The University of Alabama at Birmingham)

Washington University

patents

6. 6 out of 834,570

Other

patents

Years Active: 2002-2020

Loading Chart...

Areas of Expertise:

Alphavirus

Recombinant Vectors

Immune Response

Encephalitis Virus

Chimeric Viruses

Pseudoinfectious

Venezuelan Equine Encephalitis

Vector Systems

Structural Proteins

Genome Mutations

Attenuation

Alphavirus Replicons

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10533186 - Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof (2020-01-14),

2. 9580690 - Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof (2017-02-28),

3. 9402890 - Methods and compositions for pseudoinfectious alphaviruses (2016-08-02),

4. 9273288 - Pseudoinfectious flavivirus and uses thereof (2016-03-01),

5. 8961995 - Methods and compositions for alphavirus replicons (2015-02-24),

6. 8748591 - Chimeric sindbis-western equine encephalitis virus and uses thereof (2014-06-10),

7. 8647864 - Compositions and methods for generating an immune response utilizing alphavirus-based vector systems (2014-02-11),

8. 8614082 - Attenuation of encephalitogenic alphavirus and uses thereof (2013-12-24),

9. 8426188 - Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof (2013-04-23),

10. 8394620 - Two-component genome flavivirus and uses thereof (2013-03-12),

11. 8343506 - Chimeric chikungunya virus and uses thereof (2013-01-01),

12. 8252574 - [object Object] (2012-08-28),

13. 7811812 - Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis (2010-10-12),

14. 7771979 - Compositions and methods for generating an immune response utilizing alphavirus-based vector systems (2010-08-10),

15. 7332322 - Venezuelan equine encephalitis virus replicons with adaptive mutations in the genome and uses thereof (2008-02-19),

Title: Ilya V. Frolov: Pioneering Innovations in Virology

Introduction

Ilya V. Frolov is an esteemed inventor based in Birmingham, AL, known for his significant contributions to the field of virology. With a remarkable portfolio of 21 patents, Frolov has made substantial advancements in the development of attenuated recombinant alphaviruses, showcasing his innovative approach to addressing viral diseases.

Latest Patents

Among Frolov's latest inventions is a groundbreaking patent titled "Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof." This invention discloses a novel attenuated recombinant alphavirus designed to prevent replication in mosquito cells, thereby eliminating the potential for transmission by mosquito vectors. This innovative approach includes the use of various alphaviruses such as the Western Equine Encephalitis virus, Eastern equine encephalitis virus, Venezuelan equine encephalitis virus, and Chikungunya virus. Additionally, the patent outlines methods of generating such alphaviruses and their applications as immunogenic compositions.

Career Highlights

Frolov has held positions in reputable organizations, including the University of Texas System. His role within these institutions has allowed him to collaborate with leading researchers and refine his inventive process, leading to significant advancements in his field.

Collaborations

Throughout his career, Ilya V. Frolov has collaborated with esteemed colleagues, notably Elena Frolova and Thomas W. Dubensky, Jr. These partnerships have facilitated the exchange of knowledge and expertise, further enriching his contributions to virology and related fields.

Conclusion

Ilya V. Frolov exemplifies the spirit of innovation within the scientific community. His dedication to developing safe and effective vaccines against viral diseases highlights the importance of research and collaboration in advancing public health. With an impressive array of patents and ongoing research, Frolov continues to pave the way for future discoveries in virology.

Profile summary based on public USPTO records.